{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:32:12Z","timestamp":1773318732491,"version":"3.50.1"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy of JNJ-Q2, a new broad-spectrum fluoroquinolone (FQ), was evaluated in a murine septicemia model with methicillin-susceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MSSA) and methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            (MRSA) and in a\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Streptococcus pneumoniae<\/jats:named-content>\n            lower respiratory tract infection model. JNJ-Q2 and comparators were also evaluated in an acute murine skin infection model using a community-acquired MRSA strain and in an established skin infection (ESI) model using a hospital-acquired strain, for which the selection of resistant mutants was also determined. JNJ-Q2 demonstrated activity in the MSSA septicemia model that was comparable to that moxifloxacin (JNJ-Q2 50% effective dose [ED\n            <jats:sub>50<\/jats:sub>\n            ], 0.2 mg\/kg of body weight administered subcutaneously [s.c.] and 2 mg\/kg administered orally [p.o.]) and activity in the MRSA septicemia model that was superior to that of vancomycin (JNJ-Q2 ED\n            <jats:sub>50<\/jats:sub>\n            , 1.6 mg\/kg administered s.c.). In an\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            lower respiratory tract infection model, JNJ-Q2 displayed activity (ED\n            <jats:sub>50<\/jats:sub>\n            , 1.9 mg\/kg administered s.c. and 7.4 mg\/kg administered p.o.) that was comparable to that of gemifloxacin and superior to that of moxifloxacin. In both MRSA skin infection models, treatment with JNJ-Q2 resulted in dose-dependent reductions in bacterial titers in the skin, with the response to JNJ-Q2 at each dose exceeding the responses of the comparators ciprofloxacin, moxifloxacin, linezolid, and vancomycin. Additionally, in the ESI model, JNJ-Q2 showed a low or nondetectable propensity for ciprofloxacin resistance selection, in contrast to the selection of ciprofloxacin-resistant mutants observed for both ciprofloxacin and moxifloxacin. JNJ-Q2 demonstrated activity that was comparable or superior to the activity of fluoroquinolone or antistaphylococcal comparators in several local and systemic skin infection models performed with both\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            and is currently being evaluated in phase II human clinical trials.\n          <\/jats:p>","DOI":"10.1128\/aac.00471-11","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T06:41:38Z","timestamp":1315896098000},"page":"5522-5528","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of a New Fluoroquinolone, JNJ-Q2, in Murine Models of Staphylococcus aureus and Streptococcus pneumoniae Skin, Respiratory, and Systemic Infections"],"prefix":"10.1128","volume":"55","author":[{"given":"Jeffrey","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamese J.","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Melton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"Present address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred M.","family":"Barron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Simon","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.02.002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2771-2777.2004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.03.010"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp210"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01150-08"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.6.1279"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.7.2636-2640.1992"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1655"},{"key":"e_1_3_2_10_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20147th ed., vol. 29. CLSI document M07-A7","author":"CLSI","year":"2009","unstructured":"CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20147th ed., vol. 29. CLSI document M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/597044"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2008.0805"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2008.09.suppl52.283"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-09"},{"key":"e_1_3_2_15_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Fernandez J.","year":"2010","unstructured":"FernandezJ.. 2010. Efficacy of a new fluoroquinolone (FQ) JNJ-Q2 in murine models of Staphylococcus aureus and Streptococcus pneumoniae infection, abstr. F1-2093. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.12.009"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-08"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00853-07"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq252"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900743106"},{"key":"e_1_3_2_22_2","volume-title":"SAS for mixed models","author":"Little R. C.","year":"2006","unstructured":"LittleR. C. MillikenG. A. StroupW. W. WolfingerR. D. SchabenbgergerO.. 2006. SAS for mixed models. SAS Institute, Inc., Cary, NC."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2001.13.5.563"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.85"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01374-09"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00470-11"},{"key":"e_1_3_2_27_2","first-page":"155","volume-title":"Antimicrobial pharmacodynamics in theory and clinical practice","author":"Owens R. C.","year":"2002","unstructured":"OwensR. C.Jr. AmbroseP. G.. 2002. Pharmacodynamics of quinolones, p. 155\u2013176. In NightingaleC. H. MurakawaT. AmbroseP. G. (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker Inc., New York, NY."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4754-4761.2004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.11.002"},{"key":"e_1_3_2_30_2","volume-title":"The logistic procedure; SAS\/STAT 9.2 user's guide","author":"SAS Institute","year":"2008","unstructured":"SAS Institute. 2008. The logistic procedure; SAS\/STAT 9.2 user's guide. SAS Institute, Inc., Cary, NC."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.69"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2098-2101.2005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm361"},{"key":"e_1_3_2_34_2","volume-title":"Multiple comparisons and multiple tests using the SASTM system","author":"Westfall P. H. T.","year":"1999","unstructured":"WestfallP. H. T. RomR. D. D. WolfingerR. D. HochbergY.. 1999. Multiple comparisons and multiple tests using the SASTM system. SAS Institute Inc., Cary, NC."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00471-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00471-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:23:19Z","timestamp":1645485799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00471-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1128\/AAC.00471-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00471-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"2011-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}